Angela M. DemicheleBA, MD, MSCE
Dr. DeMichele co-leads the Breast Cancer Research Program of the Abramson Cancer Center and directs the Doris Duke Clinical Research Fellowship Program at Penn. Her research focuses on identifying markers of outcome, response to therapy and development of targeted therapeutics. She is currently the principal investigator of numerous clinical trials and epidemiologic studies and serves as chair of trial operations for the I-SPY2 Trial, a multicenter clinical trial in which targeted therapeutics are tested in the context of molecular and MRI response profiles in patients receiving neoadjuvant therapy for locally-advanced breast cancer.
In addition, she directs Penn’s Breast Cancer Survivorship Program, a multidisciplinary clinical research program at the Abramson Cancer Center, where she and her colleagues are performing studies of bone loss, ovarian dysfunction, hot flashes, lymphedema, depression/distress and physical activity in breast cancer survivors. At the Washington University School of Medicine, she was a Four Schools Physician/Scientist Scholar. She received her clinical training in Internal Medicine and Hematology/Oncology at Penn and joined the faculty in 2000 as a breast cancer oncologist and molecular epidemiologist.